ロード中...
Efficacy of Metreleptin Treatment in Familial Partial Lipodystrophy Due to PPARG vs LMNA Pathogenic Variants
CONTEXT: Familial partial lipodystrophy (FPLD) is most commonly caused by pathogenic variants in LMNA and PPARG. Leptin replacement with metreleptin has largely been studied in the LMNA group. OBJECTIVE: To understand the efficacy of metreleptin in PPARG vs LMNA pathogenic variants and investigate p...
保存先:
| 出版年: | J Clin Endocrinol Metab |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Endocrine Society
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6563798/ https://ncbi.nlm.nih.gov/pubmed/31194872 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2018-02787 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|